The role of calcitonin gene related peptide (CGRP) in neuropathic pain was investigated in a mouse model of neuropathic pain, spinal nerve L5 transection (L5Tx). Intrathecal injection (i.t.) of CGRP 8-37, a CGRP antagonist, significantly reduced L5Tx-induced mechanical hypersensitivity and lumbar spinal cord CCL5 expression. i. t. injection of a CCL5 neutralizing antibody significantly inhibited L5Tx-induced mechanical hypersensitivity. Further, pre-treatment with a p38-inhibitor, SB203580, was able to reduce CGRP-induced mechanical hypersensitivity, but not CGRP-induced CCL5 production. Our data indicate that CGRP can play its pro-nociceptive role through both a spinal cord CCL5-dependent, p38-independent pathway, and a p38-depenented, CCL5-independent pathway.
Introduction
Defined as pain caused by a lesion or disease of the somatosensory system, neuropathic pain is one of the most devastating kinds of chronic pain. Neuroimmune interaction is believed to play an important role in the development of neuropathic pain (DeLeo et al., 2004; Ji and Suter, 2007; Milligan and Watkins, 2009; Tsuda et al., 2005) .
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide within the calcitonin peptide family, and is widely distributed in both the peripheral and the central nervous systems. Produced largely by medium and small diameter primary afferent neurons, CGRP is important in modulating pain perception. Despite some controversy, studies have provided evidence that CGRP plays a pronociceptive role under various conditions. For example, in rodents intrathecal injection of CGRP produced significant hyperalgesia in rodents to both mechanical and thermal stimuli (Cridland and Henry, 1989; Oku et al., 1987) . Administration of a CGRP antagonist has been shown to reduce both thermal and mechanical hypersensitivity in non-injured rats and rats with inflammatory pain or neuropathic pain-like behaviors (Bennett et al., 2000a; Lee and Kim, 2007; Yu et al., 1996a; Yu et al., 1996b) . Further, spinal nerve ligation (SNL) markedly enhanced capsaicin-evoked CGRP release in lumbar spinal cord tissue in rats, suggesting a potentially increased functional activity of CGRP+ nociceptors following-nerve injury (Gardell et al., 2003) . Previously, we have observed a significant increase of CGRP expression in the lumbar spinal cord in mice following spinal nerve L5 transection (L5Tx), a murine model of neuropathic pain. In the current study we set out to assess the role of CGRP in neuropathic pain-like behaviors following L5Tx.
It has been established that numerous chemokines are involved in the development of neuropathic pain (Gao and Ji, 2010b; White et al., 2007) . For example, CCR2 knockout mice (receptor for CCL2) displayed impaired neuropathic pain responses (Abbadie et al., 2003) . Blocking CCL2 (monocyte chemoattractant protein-1 (MCP-1)) signaling via a neutralizing antibody prevented the development of SNL-induced sensory hypersensitivities (Gao et al., 2009) . Further, mice either lacking CCL5 (regulated on activation, normal T cell expressed and secreted (RANTES)) or peritoneally administered with a selective CCL5 receptor antagonist, Met-RANTES, showed reduced hypersensitivity following partial sciatic nerve ligation (Liou et al., 2013; Liou et al., 2012) . Injections of CCL5 either peripherally (Oh et al., 2001) or centrally (Benamar et al., 2008) induced hypersensitivities in rat. In addition, CX3CL1/CX3CR1 signaling and other chemokines, such as, CXCL1, CCL21 have also been implicated in the development of neuropathic
